Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
Stroke · 2023-11 · 54 (11) · 2724-2736
DOI: 10.1161/strokeaha.123.044113 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2023-11. Verfasst von Thalia S Field und 37 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver Stroke Program, Division of Neurology (T.S.F., V.D., M.K.V., P.K-A., N.R., S.M., S.C.V.G., L.K.W., O.R.B.), University of British Columbia,…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Venous Thrombosis. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of adverse outcomes such as major bleeding and functional dependence. To facilitate the design of future CVT trials, SECRET (Study of Rivaroxaban for Cerebral Venous Thrombosis) assessed (1) the feasibility of recruitment, (2) the safety of rivaroxaban compared with standard-of-care anticoagulation, and (3) patient-centered functional outcomes. METHODS: This was a phase II, prospective, open-label blinded-end point 1:1 randomized trial conducted at 12 Canadian centers. Participants were aged ≥18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were randomized to receive rivaroxaban 20 mg daily, or standard-of-care anticoagulation (warfarin, target international normalized ratio, 2.0–3.0, or low-molecular-weight heparin) for 180 days, with optional extension up to 365 days. Primary outcomes were annual rate of recruitment (feasibility); and a composite of symptomatic intracranial hemorrhage, major extracranial hemorrhage, or mortality at 180 days (safety). Secondary outcomes included recurrent venous thromboembolism, recanalization, clinically relevant nonmajor bleeding, and functional and patient-reported outcomes (modified Rankin Scale, quality of life, headache, mood, fatigue, and cognition) at days 180 and 365. RESULTS: Fifty-five participants were randomized. The rate of recruitment was 21.3 participants/year; 57% of eligible candidates consented. Median age was 48.0 years (interquartile range, 38.5–73.2); 66% were female. There was 1 primary event (symptomatic intracranial hemorrhage), 2 clinically relevant nonmajor bleeding events, and 1 recurrent CVT by day 180, all in the rivaroxaban group. All participants in both arms had at least partial recanalization by day 180. At enrollment, both groups on average reported reduced quality of life, low mood, fatigue, and headache with impaired cognitive performance. All metrics improved markedly by day 180. CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03178864.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vancouver Stroke Program, Division of Neurology (T.S.F., V.D., M.K.V., P.K-A., N.R., S.M., S.C.V.G., L.K.W., O.R.B.), University of British Columbia, Canada.
- Department of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (M.A.A., F.B., I.A., A.M.D., M.D.H.).
- Department of Radiology, Tours University Hospital, France (F.B.).
- School of Population and Public Health, and Centre for Health Outcomes and Evaluative Sciences (H.W., M.N.), University of British Columbia, Canada.
- Division of Neurology, University of Saskatchewan College of Medicine, Saskatoon, Canada (B.R.G.).
- Department of Clinical Neurosciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada (L.A.S., J.M.).
ORCID-Profile: Mohammed A Almekhlafi, Fouzi Bala, Ibrahim Alhabli, Hubert Wong, Monica Norena, Stephen C Van Gaal, Luciano A Sposato, Dylan Blacquiere, Brian M Dewar, Mark I Boulos, Brian H Buck, Kanjana S Perera, Aleksandra Pikula, George Medvedev, Carolyn Canfield, W Ben Mortenson, Sohaila Alshimemeri, Andrew M Demchuk, Dar Dowlatshahi, Sylvain Lanthier, Agnes Y Y Lee, Jennifer Mandzia, Jeffrey I Weitz
Förderung
- NINDS NIH HHS
Zitieren
APA
Field, T. S., Dizonno, V., Almekhlafi, M. A., Bala, F., Alhabli, I., Wong, H., Norena, M., Villaluna, M. K., King-Azote, P., Ratnaweera, N., Mancini, S., Van Gaal, S. C., Wilson, L. K., Graham, B. R., Sposato, L. A., Blacquiere, D., Dewar, B. M., Boulos, M. I., Buck, B. H., …, & SECRET Investigators (2023). Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke, 54(11), 2724-2736. https://doi.org/10.1161/strokeaha.123.044113
Vancouver
Field TS, Dizonno V, Almekhlafi MA, Bala F, Alhabli I, Wong H, et al. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke. 2023;54(11):2724-2736. doi:10.1161/strokeaha.123.044113
BibTeX
@article{Field2023,
author = {Field, Thalia S and Dizonno, Vanessa and Almekhlafi, Mohammed A and Bala, Fouzi and Alhabli, Ibrahim and Wong, Hubert and Norena, Monica and Villaluna, Maria Karina and King-Azote, Princess and Ratnaweera, Namali and Mancini, Steven and Van Gaal, Stephen C and Wilson, Laura K and Graham, Brett R and Sposato, Luciano A and Blacquiere, Dylan and Dewar, Brian M and Boulos, Mark I and Buck, Brian H and Odier, Celine and Perera, Kanjana S and Pikula, Aleksandra and Tkach, Aleksander and Medvedev, George and Canfield, Carolyn and Mortenson, W Ben and Nadeau, Janel O and Alshimemeri, Sohaila and Benavente, Oscar R and Demchuk, Andrew M and Dowlatshahi, Dar and Lanthier, Sylvain and Lee, Agnes Y Y and Mandzia, Jennifer and Suryanarayan, Deepa and Weitz, Jeffrey I and Hill, Michael D and SECRET Investigators, SECRET Investigators},
title = {Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis},
journal = {Stroke},
year = {2023},
volume = {54},
number = {11},
pages = {2724--2736},
doi = {10.1161/strokeaha.123.044113}
}
EUVIMED